Noel Clarke, MBBS, FRCS, ChM, Consultant Urologist, Salford Royal Hospital, explains the PROpel study design, what the overall survival data shows at data cutoff 3, and the further analysis needed to help validate the abiraterone-plus-olaparib combination as a first-line option for patients with mCRPC.
PROpel: Final OS of First-Line Abiraterone Plus Olaparib for mCRPC
By Noel Clarke, MBBS, FRCS, ChM - Last Updated: February 24, 2023Post Tags:ASCO GU 2023-Prostate Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.